Background: Androgenetic alopecia (AGA) is a common, progressive form of hair loss affecting both sexes. This controlled
study aims to assess the comparative efficacy of subcutaneous adipose-derived mesenchymal stem cells (AD-MSCs) in
combination with oral minoxidil (3 mg daily) versus oral minoxidil alone (3 mg daily) in treating AGA.
Methods: A total of 35 patients were enrolled, with 20 patients (average age 37) receiving the combination therapy of AD
MSCs and oral minoxidil, and 15 patients (average age 39) constituting the control group treated with oral minoxidil alone.
Clinical efficacy was evaluated at six months using digital trichoscopy, focusing on parameters such as hair shaft diameter,
follicular density, and the extent of follicular miniaturization. Statistical comparisons were made using Student’s t-test to
evaluate the significance of the differences observed between the two groups.
Results: Patients treated with the combination of AD-MSCs and oral minoxidil exhibited a statistically significant
improvement in all hair growth parameters when compared to the control group. Mean improvements in the combination
therapy group ranged from 25%-40%, while the control group exhibited marginal gains of 5%-10%.
Conclusion: The combination of AD-MSCs and oral minoxidil demonstrates superior therapeutic efficacy in treating AGA
compared to oral minoxidil monotherapy, offering a potential advancement in hair restoration protocols.